Background
GenoME Diagnostics builds on almost a decade of research performed by our founders Dr Paul Mullan, Dr James Beirne and Dr Laura Feeney. Our lead product, OvaME, detects DNA methylation changes in a minimal blood volume and can be analysed on highly sensitive, yet user-friendly, droplet digital PCR technology.
Our cutting-edge approach to biomarker identification in ovarian cancer means OvaME has the potential to detect changes in the very earliest stages of disease. Our aim is to improve upon the current CA125 assay and the ovarian cancer diagnostic pathway.
Improved diagnostics bring value to all stages of healthcare
Beyond ovarian cancer
Our novel diagnostic pipeline can be utilised for biomarker in discovery in a wide range of disease and applications, such as companion diagnostics for patient selection and stratification, disease monitoring, or early diagnosis in other disease areas.
Patrick G Johnston Centre
for Cancer Research
97 Lisburn Road
Belfast BT9 7AY
Northern Ireland
+44 (0)79 7205 6063
info@genomediagnostics.co.uk
